Regimen Reference Order – BRST – T-DM1 (Kadcyla®) Adjuvant

ARIA: BRST – [T-DM1 (Kadcyla) ADJUVANT]

Planned Course: Every 3 weeks for 14 cycles
Indication for Use: Breast Cancer HER2 positive Adjuvant; Post Neo-adjuvant

CVAD: At Provider's Discretion

Proceed with treatment if:
ANC equal to or greater than 1.5 x 10^9/L AND Platelets equal to or greater than 50 x 10^9/L

- **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – T-DM1 (Kadcyla®) Adjuvant

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Cycle 1 Only		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
T-DM1 (Kadcyla®)	3.6 mg/kg	IV in normal saline 250 mL over 90 minutes Use 0.2 or 0.22 micron filter **Alert*: *Ensure that T-DM1 (brand name Kadcyla®) is dispensed and administered*
Cycle 2 and Onwards		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
T-DM1 (Kadcyla®)	3.6 mg/kg	IV in normal saline 250 mL over 30 minutes Use 0.2 or 0.22 micron filter **Alert*: *Ensure that T-DM1 (brand name Kadcyla®) is dispensed and administered*

All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See BRST DSG – Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

All Cycles

- CBC and biochemistry as per Physician Orders

Cardiac Monitoring

- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and every 4 cycles

Cycle 1 Only

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- Observe patient for 90 minutes after administration
- Full vital signs prior to discharge

Cycle 2 and Onwards

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after administration of Cycles 2 and 3 only
- Full vital signs prior to discharge

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- T-DM1 (Kadcyla®) is also called trastuzumab emtansine
- There is a risk of medication errors between T-DM1 (Kadcyla®) and trastuzumab. In order to minimize the risk, check the regimen ordered, the vial labels, and the prescription label to ensure that the drug being prepared and administered is T-DM1 (Kadcyla®)